Chinese pharmaceutical group with a leading position in anesthetic and pain-management drugs, plus broader generics and healthcare businesses.
Chinese pharmaceutical group with a leading position in anesthetic and pain-management drugs, plus broader generics and healthcare businesses.
Sells prescription drugs to hospitals, where its anaesthetics and pain relievers hold a strong position because they are tightly controlled substances that few makers are licensed to produce. Hospital pricing is shaped by China's government-led bulk-purchase tenders, which cut prices in exchange for volume. It also owns a US generic-drug business.
Moat: narrow (regulatory licence, brand). Controlled-substance manufacturing licences for anesthetics are hard to obtain, protecting incumbents.
Headquarters: Wuhan, China · Employees: 17,153
Size Humanwell Healthcare (Group) (600079.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $4.87B, the 481st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥20.12 on 18 Nov 2026.
Performance Over six months the shares gained 10.6%, against +10.5% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 1.5% over the last twelve months (peer median +13.1%); the operating margin is 15.1% (peer median 20.6%).
Valuation It trades at 13.8× forward earnings against a peer median of 28.7× (5th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.3 points above its cost of capital (5.0% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥24.5B | CN¥23.8B | CN¥25.3B | CN¥24.4B | CN¥22.2B |
| Revenue growth | — | -6% | +4% | +10% | — |
| Gross profit | CN¥12.5B | CN¥10.9B | CN¥10.6B | CN¥10.7B | CN¥9.21B |
| EBITDA | n/a | CN¥4.60B | CN¥3.91B | CN¥4.10B | CN¥3.57B |
| Net income | CN¥2.58B | CN¥1.86B | CN¥1.33B | CN¥2.13B | CN¥2.48B |
| Free cash flow | CN¥2.11B | CN¥1.83B | CN¥1.17B | CN¥89.4M | -CN¥621M |
| Capital expenditure | CN¥545M | CN¥733M | CN¥1.02B | CN¥1.96B | CN¥3.11B |
| Total debt | CN¥8.15B | CN¥8.99B | CN¥9.52B | CN¥9.95B | CN¥11.0B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Humanwell Healthcare (Group) 600079.SS | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% |
| Haisco Pharmaceutical 002653.SZ | $9.13B | +2% | +42% | 18% | 36.0× | 19.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600079.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.9% | -1.3% | 8th highest of 21 |
| 6-month return | +10.6% | +10.5% | 11th highest of 21 |
| Distance from 52-week high | -4.0% | -30.1% | 4th highest of 21 |
| Revenue growth (TTM) | +1.5% | +13.1% | 5th lowest of 19 |
| Operating margin | 15.1% | 20.6% | 7th lowest of 19 |
| Forward P/E | 13.8× | 28.7× | 5th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -8.8% | 7.3% | 2nd least demanding of 17 |
| Growth delivered (Del g) | +3.0% | +13.0% | 3rd lowest of 17 |
| Hurdle (Req g minus delivered) | -11.8 pp | -2.6 pp | 6th least demanding of 17 |
| ROIC minus cost of capital | +6.3 pp | +3.4 pp | 7th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% | +3.0% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 17.1× | 17.3% | +19.9% |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% | +6.2% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% | +5.5% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 33.6× | 15.9% | +12.7% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 31.1× | 16.5% | +12.2% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% | +35.4% |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% | +93.6% |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% | +192.5% |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | n/a | n/a | n/a |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.48B | -23% | +6% | 3% | 7.0× | 1.3% | +4.0% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% | +519.6% |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% | -2.6% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 31.7× | 23.8% | +13.8% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 16.2× | -9.9% | +0.3% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 45.1× | 7.9% | +46.5% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $4.31B | -24% | +14% | 11% | 35.4× | 12.4% | +9.7% |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 25.8× | n/a | n/a |
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 39.3× | 20.2% | +13.3% |